China-based XellSmart Biopharmaceutical Co., Ltd. announced that the US FDA has granted Fast Track Designation (FTD) to XS411, an allogeneic, off-the-shelf, induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell therapy, for the treatment of Parkinson's disease. The designation positions XS411 for rolling Biologics License Application (BLA) submission and eligibility for Priority Review upon meeting specified clinical endpoints, accelerating a US regulatory pathway for a cell therapy class that has no approved representative in any major market.
XS411 works by delivering iPSC-derived dopaminergic neural progenitor cells via intracerebral transplantation into the putamen, where the cells are intended to engraft, differentiate, and restore dopamine synthesis — replacing neurons lost to the progressive degeneration characteristic of Parkinson's disease. No currently approved therapy modifies this underlying neurodegenerative process; existing treatments manage symptoms only.
The FTD follows Phase I data from a registrational trial at Beijing Tiantan Hospital, in which patients with moderate-to-severe Parkinson's disease achieved statistically significant improvements in motor scores and improved quality-of-life metrics following a single transplantation. With follow-up exceeding 12 months across enrolled patients, the company reported no cell therapy-related adverse events, including no graft-induced dyskinesia, tumorigenic proliferation, or immune rejection.
Those Phase I results supported the launch of a multicenter Phase II registrational trial in China, which completed enrollment in July 2026. The trial employs a Prospective, Randomized, Open-label, Blinded Endpoint Assessment (PROBE) design across five institutions including Beijing Tiantan Hospital, Peking Union Medical College Hospital, and West China Hospital, Sichuan University, enrolling 30 patients aged 50–75 years with primary Parkinson's disease and disease duration of 5 to 15 years, randomized 2:1 to XS411 or standard pharmacotherapy with a 12-month primary follow-up period.